News – Page 37 – Alligator Bioscience

2020-06-10

Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High D ...

2020-06-04

Regulatory

Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced ...

2020-06-01

Regulatory

Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 ...

2020-05-29

Regulatory

Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data ...

2020-05-05

Lund, Sweden, May 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX),today announces that an annual general meeting was held in the co ...

2020-04-27

Regulatory

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the o ...

2020-04-23

Regulatory

Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...

2020-04-20

Lund, Sweden, April 20, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company's Nomination Committee, ...

2020-04-07

Regulatory

Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...